Publikationer

Prostate Cancer data Base Sweden (PCBaSe), en unik databas för prostatacancerforskning

Prostatacancer är en sjukdom med extremt varierande förlopp beroende på tumörkarakteristika. Studier av prostatacancer måste därför innefatta tumörkarakteristika för att ge meningsfull information. I Nationella prostatacancerregistret (NPCR) registreras sedan starten av registret 98% av alla incidenta fall av prostatacancer i Sverige avseende tumörkarakteristika och behandling inom 6 månader efter diagnosdatum.

Via länkningar av NPCR med Cancerregistret, Dödsorsaksregistret, Patientregistret och Läkemedelsförskrivningsregistret på  Socialstyrelsen och Personregistret, LISA (socioekonomisk databas) och Flergenerationsregistret vid SCB har PCBaSe skapats för prostatacancerforskning. PCBaSe innehåller förutom alla fall av prostatacancer diagnostiserade sedan 1998 i Sverige också fem kontrollmän fria från prostatacancer för varje fall matchade för födelseår och bostadslän.

PCBaSe innehåller data avseende sjukhusvård, operationer, läkemedelsuttag, dödsorsaker och möjliggör undersökningar av bl a vårdmönster och kliniskt förlopp bland 150 000 män med prostatacancer. Sedan 2010 har mer än  200 vetenskapliga artiklar baserade på PCBaSe publicerats.

Ansvarig forskare för PCBaSe är professor Pär Stattin, Urologkliniken och Inst. Kirurgiska vetenskaper, Akademiska sjukhuset och Uppsala universitet.

mail: par.stattin@surgsci.uu.se 

  • Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies.

    BMC Med Res Methodol. 2018 Dec 5;18(1):161.
    Carlsson J, Davidsson S, Fridfeldt J, Giunchi F, Fiano V, Grasso C, Zelic R, Richiardi L, Andrén O, Pettersson A, Fiorentino M, Akre O.

  • Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.

    Eur Urol. 2018 Dec;74(6):710-719.
    Li W, Middha M, Bicak M, Sjoberg DD, Vertosick E, Dahlin A, Häggström C, Hallmans G, Rönn AC, Stattin P, Melander O, Ulmert D, Lilja H, Klein RJ.

  • Germline variation at 8q24 and prostate cancer risk in men of European ancestry.

    Nat Commun. 2018 Nov 5;9(1):4616.
    Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C, Mucci L, Kraft P, Cancel-Tassin G, Sorensen KD, Maehle L, Grindedal EM, Strom SS, Neal DE, Hamdy FC, Donovan JL, Travis RC, Hamilton RJ, Rosenstein B, Lu YJ, Giles GG, Kibel AS, Vega A, Bensen JT, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Schaid DJ, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Wiklund F, Chanock SJ, Easton DF, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA.

  • Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus.

    Int J Cancer. M2018 Oct 15;143(8):1868-1875.
    Häggström C, Van Hemelrijck M, Garmo H, Robinson D, Stattin P, Rowley M, Coolen ACC, Holmberg L.

  • Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden.

    Scand J Urol. 2018 Aug;52(4):277-284.
    Nugin H, Folkvaljon Y, Damber JE, Adolfsson J, Robinson D, Stattin P.

  • Public online reporting from a nationwide population-based clinical prostate cancer register.

    BJU Int. 2018 Jul;122(1):8-10.
    Stattin P, Sandin F, Loeb S, Robinson D, Franck Lissbrant I, Lambe M.

  • Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study.

    Am J Epidemiol. 2019 Jun 1;188.
    Zelic R, Zugna D, Bottai M, Andrén O, Fridfeldt J, Carlsson J, Davidsson S, Fiano V, Fiorentino M, Giunchi F, Grasso C, Lianas L, Mascia C, Molinaro L, Zanetti G, Richiardi L, Pettersson A, Akre O.

  • Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer

    J Clin Oncol. 2018 Jun 20;36(18):1847-1852.
    Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O.

  • Data quality in the National Prostate Cancer Register (NPCR) of Sweden.

    Umeå University Dissertations New Series No 1945. ISSN 0346-6612
    Katarina Tomic.

  • Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study.

    Int J Cancer. 2018 Jun 15;142(12):2478-2484.
    Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P.

  • Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study

    Int J Cancer. 2018 Jun 1;142(11):2254-2262.
    Arthur R, Williams R, Garmo H, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinsson D, Jungner I, Van Hemelrijck M.

  • Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.

    Prostate Cancer Prostatic Dis. 2018 Jun;21(2):228-237.
    FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, Wright JL, Eeles R, Kote-Jarai Z, Govindasami K, Giles GG, Southey MC, Schleutker J, Tammela TL, Sipeky C, Penney KL, Stampfer MJ, Gronberg H, Wiklund F, Stattin P, Hugosson J, Karyadi DM, Ostrander EA, Feng Z, Stanford JL.

  • Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.

    Eur Urol. 2019 Apr;75(4):676-683.
    Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.

  • A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0

    PLoS One. 2018 Apr 12;13(4):e0195690.
    Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M.

  • Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.

    Scand J Urol. 2018 Apr;52(2):143-150.
    Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, Folkvaljon Y, Stattin P.

  • Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study,

    Eur Urol. 2018 Apr;73(4):502-511.
    Robinson D, Garmo H, Lissbrant IF, Widmark A, Pettersson A, Gunnlaugsson A, Adolfsson J, Bratt O, Nilsson P, Stattin P.

  • Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study.

    BMJ Open. 2018 Mar 16;8(3):e020787.
    Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Armes J, Holmberg L, Adolfsson J, Van Hemelrijck M.

  • The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study

    BMC Med. 2018 Feb 28;16(1):31.
    Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A.

  • Association between Type 2 diabetes, curative treatment and survival in men with intermediate and high risk localised prostate cancer

    BJU Int. 2018 Feb;121(2):209-216.
    Crawley D, Garmo H, Rudman S, Stattin P, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

  • Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery

    J Surg Oncol. 2018 Feb;117(2):321-327.
    Ventimiglia E, Folkvaljon Y, Carlsson S, Bratt O, Montorsi F, Volz D, Akre O, Johansson E, Stattin P.

  • Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists

    BJU Int. 2018 Feb;121(2):260-267.
    Bosco C, Wong C, Garmo H, Crawley D, Holmberg L, Hammar N, Adolfsson J, Stattin P, Van Hemelrijck M.

  • Diagnosspecifika översikter är viktiga vertyg för cancervården

    Lakartidningen. 2018 Jan 9;115.
    Stattin P, Franck Lissbrant I.

  • The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data

    Eur J Cancer. 2018 Jan;88:101-108.
    Lycken M, Drevin L, Garmo H, Stattin P, Adolfsson J, Lissbrant IF, Holmberg L, Bill-Axelson A.